Animal and cell line studies indicate an inhibitory effect of matrix metalloproteinase 8 (MMP8) on tumorigenesis and metastasis \[[@B1]-[@B3]\]. We investigated whether *MMP8*gene variation was associated with breast cancer metastasis and prognosis in humans. We first studied nine tagging single nucleotide polymorphisms (SNPs) in the *MMP8*gene in 140 clinically and pathologically well-characterized breast cancer patients. Four of the SNPs were found to be associated with lymph node metastasis, the most pronounced being a promoter SNP (rs11225395) with its minor allele (T) associating with reduced susceptibility to lymph node metastasis (*P*= 0.02). This SNP was further evaluated for association with cancer relapse and survival among a cohort of approximately 1,100 breast cancer patients who had been followed for cancer recurrence and mortality for a median of 7.1 years. The T allele was associated with reduced cancer relapse and greater survival, particularly among patients with earlier stage cancer. Among patients of tumour-node-metastasis stage 0-II, the adjusted hazard ratio of disease-free survival was 0.7 (95% CI, 0.5 to 0.9) for patients carrying T allele compared with those homozygous for the C allele (*P*= 0.02). *In vitro*experiments showed that the T allele had higher promoter activity than the C allele in breast cancer cells. Electrophoretic mobility shift assays showed binding of nuclear proteins to the DNA sequence at the SNP site of the T allele but not that of the C allele. The data suggest that *MMP8*gene variation may influence breast cancer prognosis and support the notion that MMP8 has an inhibitory effect on cancer metastasis.
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